Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17809468 | 1.00 | SCNN1A (0.52) | SCNN1AKCNH2 | |
| SCHEMBL16383780 | 0.97 | SCNN1A (0.55) | SCNN1A | |
| SCHEMBL16383773 | 0.97 | SCNN1A (0.55) | SCNN1A | |
| SCHEMBL16383774 | 0.97 | SCNN1A (0.55) | SCNN1A | |
| SCHEMBL17809433 | 0.97 | SCNN1A (0.55) | SCNN1A | |
| SCHEMBL16383762 | 0.97 | SCNN1A (0.55) | SCNN1A | |
| SCHEMBL17809070 | 0.97 | SCNN1A (0.55) | SCNN1A | |
| SCHEMBL9913767 | 0.96 | SCNN1A (0.56) | SCNN1AKCNH2 | |
| SCHEMBL9913758 | 0.96 | SCNN1A (0.56) | SCNN1AKCNH2 | |
| SCHEMBL17919056 | 0.95 | SCNN1A (0.53) | SCNN1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656972-B2 | Compounds for treatment of cystic fibrosis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, ELANE, OTC | SCNN1A 87/4885KCNH2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.